Individual risk of post-ivermectin serious adverse events in subjects infected with
Africa
Loiasis
Serious adverse events
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high We used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemic areas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0·36%) developed an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariate logistic models including subjects' sex, age, pre-treatment The models predicted that regardless of sex, about 1% of people with 20 000 By enabling the prediction of post-ivermectin SAE risk in communities with known distribution of UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Développement; Mectizan Donation Program; Bill & Melinda Gates Foundation
Sections du résumé
BACKGROUND
BACKGROUND
Implementation of onchocerciasis elimination programmes has been delayed in Central Africa because of the risk of ivermectin-related serious adverse events (SAEs) in individuals with high
METHODS
METHODS
We used individual participant data from two trials conducted in loiasis-onchocerciasis co-endemic areas in Cameroon. among the 10 506 ivermectin-treated subjects included in the analysis, 38 (0·36%) developed an ivermectin-related SAE. To predict individual-level risk of SAE, we developed mixed multivariate logistic models including subjects' sex, age, pre-treatment
FINDINGS
RESULTS
The models predicted that regardless of sex, about 1% of people with 20 000
INTERPRETATION
CONCLUSIONS
By enabling the prediction of post-ivermectin SAE risk in communities with known distribution of
FUNDING
BACKGROUND
UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases; Institut de Recherche pour le Développement; Mectizan Donation Program; Bill & Melinda Gates Foundation
Identifiants
pubmed: 33294807
doi: 10.1016/j.eclinm.2020.100582
pii: S2589-5370(20)30326-6
pmc: PMC7700892
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100582Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Am J Vet Res. 1987 Apr;48(4):684-5
pubmed: 3592367
Am J Trop Med Hyg. 2009 Dec;81(6):1056-61
pubmed: 19996437
Curr Pharm Biotechnol. 2012 May;13(6):952-68
pubmed: 22039791
Am J Trop Med Hyg. 2014 Feb;90(2):335-8
pubmed: 24420781
Pharmacogenetics. 2001 Nov;11(8):727-33
pubmed: 11692082
Am J Trop Med Hyg. 2010 Jul;83(1):28-32
pubmed: 20595473
Am J Trop Med Hyg. 2018 Feb;98(2):382-388
pubmed: 29210346
Am J Trop Med Hyg. 2018 Jul;99(1):116-123
pubmed: 29761763
Lancet Infect Dis. 2020 Jan;20(1):102-109
pubmed: 31676244
Ophthalmic Epidemiol. 2000 Mar;7(1):27-39
pubmed: 10652169
Int Health. 2018 Mar 1;10(suppl_1):i40-i48
pubmed: 29471342
Clin Infect Dis. 2020 Apr 10;70(8):1628-1635
pubmed: 31165855
N Engl J Med. 2017 Nov 23;377(21):2044-2052
pubmed: 29116890
Lancet. 1997 Jul 5;350(9070):18-22
pubmed: 9217715